Vitamin D receptor gene polymorphisms and osteoporosis by Leeuwen, J.P.T.M. (Hans) van et al.
ELSEVIER 
Papers 
Vitamin D receptor gene 
polymorphisms and osteoporosis 
Johannes P.T.M. van Leeuwen, Andre G. Uitterlinden, Jan C. Birkenhiiger, and 
Huibert A.P. Pols* 
Departments of Internal Medicine III and of *Epidemiology, Erasmus University Medical School, 
Rotterdam, The Netherlands 
Keywords: vitamin D receptor; osteoporosis; bone; genetics; polymorphism 
Osteoporosis characterized by a decrease in bone mineral 
density (BMD) and microarchitectural deterioration of the 
bone structure leading to a higher susceptibility to frac- 
tures. 1 The burden of fractures is substantial, both for the 
individual and public health care system. The most serious, 
i.e. hip fracture, is associated with a high mortality rate of 
approximately 25% within 1 year and a considerable decline 
of physical and social functions. Hip fracture is not a rare 
event, in that the lifetime risk of a hip fracture for a 50- 
year-old woman is on average about 16%. 2 The total num- 
ber of hip fractures in The Netherlands was 10,360 in 1987, 
and it is expected that, partly as a consequence of aging of 
the population, this number will exceed 20,000 by the year 
2015. 3 
Despite advances in therapy, reversal of bone loss in 
established osteoporosis remains problematic, and deformi- 
ties and disability due to fractures often persist. Therefore, 
prevention of osteoporosis a matter of priority. Identifi- 
cation of risk factors is of utmost importance for the devel- 
opment of programs for prevention of osteoporosis. Frac- 
ture risk is largely determined by BMD, which is the result 
of the peak value achieved in the third decade of life and 
subsequent age- and menopause-related bone loss. Lifestyle 
factors, i.e. diet, physical activity, smoking etc., are deter- 
minants of BMD and are of course targets for primary pre- 
vention. Three types of observations have shown that ge- 
netic factors are also important determinants of BMD. First 
are the differences in BMD between races; blacks have a 
higher BMD even when adjusted for body weight and 
height, and in addition a lower incidence of osteoporotic 
fractures. 4 Second, twin studies have also demonstrated a 
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genetic effect. In 1973, a study by Smith et al. 5 suggested an 
important genetic omponent in the determination f BMD. 
Later this was confirmed and extended by Pocock et al., 6 
who demonstrated that BMD showed a better correlation in 
monozygotic than in dizygotic twins. A subsequent longi- 
tudinal twin study has also demonstrated a genetic effect on 
the rate of change in BMD. 7 In addition, the bone turnover 
markers type I procollagen and osteocalcin appeared to be 
under genetic influence, s'9 Third, family studies have pro- 
vided evidence for a genetic impact on BMD; daughters of 
mothers with osteoporosis have a lower BMD than daugh- 
ters of women with a normal BMD. 1°-12 Altogether, it has 
been calculated that up to 75% of BMD is genetically de- 
termined, appearing as a polygenic, quantitative trait. These 
studies thus indicate the potential of genetic research to 
identify at an early stage individuals with an increased risk 
of developing osteoporosis. 
The next, essential step in genetic research on osteopo- 
rosis is to dissect his polygenic trait into discrete genetic 
factors. Initially, the prime candidate genes are those coding 
for proteins playing a direct role in bone metabolism; it is 
also possible that further analysis of the human genome will 
reveal other important genes. At the moment, the only pub- 
lished data in relation to BMD and osteoporosis are for the 
vitamin D receptor (VDR) gene locus on chromosome 12. 
The VDR is a member of the steroid hormone receptor 
family and induces gene expression via heterodimerization 
with the retinoic X receptor and binding to a specific 
hormone response lement. 13 One of the genes strongly 
regulated by 1,25-dihydroxyvitamin D 3 is the bone-specific 
protein osteocalcin.14 1,25-Dihydroxyvitamin D 3 is the bio- 
logically most active metabolite of vitamin D 3 and is 
formed by two consecutive hydroxylation steps in the liver 
and the kidney. The seco-steroid hormone vitamin D 3 is, 
together with parathyroid hormone, the major regulatory 
hormone for calcium and bone metabolism. 
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In 1992 an association between a BsmI restriction frag- 
ment length polymorphism (RFLP) in intron 8 of the VDR 
gene and the serum osteocalcin concentration was demon- 
strated (Fig. 1). 15 This RFLP appeared to be a better pre- 
dictor of postmenopausal serum osteocalcin concentration 
than menopause. 15 This was then extended to an analysis of 
the association between the BsmI RFLP and BMD. In 1994 
Morrison et al) 6 reported on the predictability of BMD on 
the basis of VDR alleles. They showed that in a Caucasian 
population the BMDs of dizygotic twins concordant for the 
BsmI RFLP were more similar to each other than discordant 
twins, illustrating the genetic contribution of this locus to 
the variability in BMD. This was substantiated bythe analy- 
sis of the BMD of 311 healthy women, which showed that 
the "bb"  genotype was associated with a higher BMD than 
the "BB"  genotype. They calculated that the BB genotype 
reached the fracture threshold ( = 2 S.D. below peak BMD) 
8-10 years earlier than the bb genotype. In view of the fact 
that the fracture incidence doubles every 4-5 years implies 
a 4-fold higher fracture risk for the BB genotype. Together 
these observations thus show a strong association between 
RFLPs at the VDR gene locus and BMD. 
After the initial finding in this Australian population con- 
flicting results have been reported on the association of the 
diallelic BsmI RFLP in the VDR gene and BMD. Some 
studies have confirmed the association between the BsmI 
polymorphism and BMD, even in women with different 
ethnic backgroundsl7-2°; other studies, however, could not 
demonstrate an association. 21"22 There may be statistical as 
well as genetic explanations for this discrepancy, as follows. 
1) The sample size, and consequently the statistical power, 
of the previous tudies was limited. 2) There is bias, e.g. due 
to population admixture, in studies suggesting an associa- 
tion. 3) Linkage disequilibrium exists, e.g. the VDR gene 
locus itself is not causally related to BMD but is linked to a 
neighboring bone metabolism-related gene. As recombina- 
tion between the marker locus (the VDR gene) and the 
putative bone metabolism-related gene may occur at each 
meiosis, linkage disequilibrium may be found in some 
populations but not in others. 4) There may be allelic het- 
erogeneity, i.e. the VDR gene is the gene implicated in 
BMD, but different sequence variants of the gene are asso- 
ciated with BMD in different populations. The lack of as- 
sociation can then be explained by not testing for the allele 
associated with the VDR sequence variant in a particular 
population, and/or by using less informative genetic mark- 
ers to test for an association. 
At least in part these problems have been addressed by 
23 Uitterlinden et al. by the Rotterdam study, in a large eth- 
nically homogeneous population-based sample. 24 We ob- 
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Figure 1 Depiction of the localization of the polymorphic  (p) 
restriction sites for Bsml, Apal, and Taql. Note: in the last exon 
an invariant (i) Taql restriction site is present. 
served frequencies of the two alleles for the BsmI polymor- 
phism almost identical to those in other studies of Caucasian 
populations. ~6'18-22 Despite the large population analyzed 
(798) only a weak association between the BsmI RFLP and 
BMD was observed in women, and none in men. The dial- 
lelic BsmI RFLP has a low genetic resolution in that it 
discriminates only two alleles reflecting three genotypes, 
which can thus diminish particular associations. To increase 
the genetic resolution we developed a direct haplotyping 
polymerase chain reaction test to monitor three clustered 
(BsmI, ApaI, and TaqI) RFLPs. As opposed to BsmI analy- 
sis, which detects three different genotypes, direct haplo- 
typing can identify 12 different genotypes. In addition, 
instead of 5-6%, differences in BMD between extreme 
genotypes now amounted to 18-25%. 23 These data show 
that probably part of the failure of several previous tudies 
to detect an association could be attributed to sample size 
and to the use of a minimally informative diaUelic RFLP. 
This is best illustrated by the fact that the "bAT-baT" and 
"baT-baT" genotypes have the second highest femoral 
neck BMD levels and the "bAT-bAT" genotype the lowest 
BMD, despite the fact that all are homozygous "bb"  ("B,"  
"A ,"  "T ,"  and "b,"  "a,"  " t "  denote the absence and 
presence of the BsmI, ApaI, and TaqI restriction sites, re- 
spectively). 
Surprisingly, in the Rotterdam study, the association of 
particular VDR haplotype alleles with extreme BMD values 
is different from what was reported earlier, i.e. that the "b"  
allele is associated with high and the "B"  allele with low 
BMD levels.t6-2° In contrast, we find the "BAt"  haplotype 
allele (as one representative of the group with "B"  alleles) 
to be associated with high BMD levels and the "bAT"  
haplotype allele (as one representative of the group with 
"b"  alleles) with low levels. Our data thus suggest hat 
there is allelic heterogeneity at the VDR locus among dif- 
ferent populations. Alternatively, we cannot exclude that the 
VDR gene is in linkage disequilibrium with another bone 
metabolism-related gene and that recombination has oc- 
curred in our study population. In this respect, a more com- 
prehensive analysis of sequence variation in functionally 
relevant parts of the VDR locus and in its chromosomal 
vicinity will assist in making this distinction. 
One important consideration is that the polymorphisms 
used to explore associations between VDR alleles and BMD 
are anonymous polymorphisms, i.e. they do not code for 
different amino acids in the VDR protein. Therefore, a ma- 
jor question is how these allelic differences might relate to 
functional differences. In the initial study of Morrison et al. 16 
it was suggested that sequence variation in the 3'- 
untranslated region (UTR) of the VDR gene could be re- 
lated to differences in expression of the gene. Sequencing of 
the 3.2-kilobase 3'-UTR of two BsmI VDR genotypes, BB 
and bb, revealed differences at 13 sites. When these two 
3'-UTRs were inserted ownstream of a murine mammary 
tumor virus long terminal repeat-driven luciferase reporter 
gene construct and transfected into COS-7 kidney cells and 
ROS17/2.8 osteoblast-like cells substantial differences in 
luciferase activity between the two UTRs were observed. In 
general, the 3'-UTR of mRNAs has been suggested to be 
involved in determining mRNA stability and mRNA routing 
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toward cellular locations where translation takes place. 25'26 
Sequence variations in this part of the mRNA may thus play 
an important role in defining subtle differences in expres- 
sion levels and/or expression mechanisms between different 
alleles. 
Indications that the VDR gene variations may have a 
functional impact have come from a recent study on 21 
twins by the Australian group. 27 In the BB genotype group 
(low BMD) baseline osteocalcin, 1,25-dihydroxyvitamin D 3 
(1,25-(OH)zD3), type I collagen, and inorganic phosphate 
levels were significantly higher. Treatment for 7 days with 
2 t~g of oral 1,25-(OH)2D 3 resulted in differences in re- 
sponses, in that induction of osteocalcin synthesis and sup- 
pression of serum intact parathyroid hormone was more 
marked in the "bb" genotype, and stimulation of urinary 
calcium and hydroxyproline excretion in the "BB"  geno- 
type. In addition, a recent study has reported reduction in 
bone loss after calcium supplementation n a particular BsmI 
VDR genotype. 2sHowever, these data are far from conclu- 
sive, and a detailed analysis of the functional consequences 
of the various VDR genotypes i needed. In this context it 
is pertinent to mention that little is known about the con- 
tribution of natural allelic variants in receptor genes to the 
diversity of response to hormones in normal physiology and 
in diseases. 
In conclusion, polymorphisms atthe vitamin D receptor 
locus on chromosome 12 are associated with BMD. Dem- 
onstration of this association is the first step in the genetic 
dissection of the complex trait of osteoporosis and in the 
development of an early predictor for the risk of osteopo- 
rosis. Functional analysis of polymorphisms i essential, 
and ultimately identification of other loci/genes associated 
with BMD, rate of bone loss, and fracture rate will be re- 
quired for optimal prediction, prevention, and therapy. 
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